Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan [0.03%]
入院服用沙库必曲缬沙坦的处方情况透视观点摘要
Michael Gillette,Biykem Bozkurt
Michael Gillette
Heart failure is a major public health concern with a rising prevalence and significant financial detriment. Although sacubitril/valsartan was shown to reduce the risk of death and hospitalization from heart failure in a contemporary cohort...
Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders [0.03%]
直接口服抗凝药在选择性高凝状态患者中的应用
Sara M Valanejad,Kyle A Davis
Sara M Valanejad
Objective: To summarize the literature assessing the safety and efficacy of direct oral anticoagulants (DOACs) for the acute treatment and secondary prevention of venous thromboembolism (VTE) in select patients with hyper...
Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer [0.03%]
吉西他滨引起的血管痛的危险因素在胰腺癌患者中
Shigeru Ishida,Yoko Makihara,Hiroyuki Watanabe et al.
Shigeru Ishida et al.
Background: Peripheral intravenous injection of gemcitabine often causes vascular pain; however, preventive measures have not yet been established. Object...
Impact of Obesity on Warfarin Reversal With Fixed-Dose Factor VIII Inhibitor Bypassing Activity (aPCC) [0.03%]
肥胖对固定剂量因子VIII抑制物旁路活性(aPCC)逆转华法林的影响
Amanda L McKinney,Lindsey M Dailey,James C McMillen et al.
Amanda L McKinney et al.
Background: Data are limited addressing anticoagulant reversal in obese patients using activated prothrombin complex concentrate (aPCC). Objective: ...
Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes [0.03%]
直接口服抗凝剂用于患有静脉血栓栓塞的慢性肾病和透析患者：系统综述血栓和出血结果
Catherine Y S Cheung,Jash Parikh,Ashley Farrell et al.
Catherine Y S Cheung et al.
Objective: To evaluate how treatment with DOACs for VTE affects thrombosis and bleeding outcomes compared to warfarin in CKD and dialysis patients. Data s...
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer [0.03%]
Sacituzumab Govitecan-hziy：治疗耐药转移性三阴性乳腺癌的抗体偶联药物
John M Seligson,Alexandra M Patron,Michael J Berger et al.
John M Seligson et al.
Objective: To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therap...
Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases [0.03%]
在有骨转移的非小细胞肺癌和小细胞肺癌患者中，唑来膦酸延长间隔给药与常规给药对骨骼事件的影响研究
Andrew H Tam,Allison J Schepers,Angel Qin et al.
Andrew H Tam et al.
Background: Zoledronic acid every 4 weeks (Q4wk) reduces the incidence of skeletal-related events (SREs) in patients with metastatic lung cancer. Lung cancer patients were excluded from extended-interval dosing trials (ev...
Lindsey Sawtelle,Lisa M Holle
Lindsey Sawtelle
Objective: To review pharmacology, available dosage forms, efficacy, and safety of cannabis and cannabinoids in cancer patients. Data sources: ...
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis [0.03%]
系统回顾和荟萃分析吡菲尼酮、尼达尼布和培美曲珠单抗在特发性肺纤维化治疗中的应用
Enrica Di Martino,Alessio Provenzani,Patrizio Vitulo et al.
Enrica Di Martino et al.
Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. ...
Vitamin D Supplementation During Statin Rechallenge in Patients With a History of Intolerance [0.03%]
他汀类药物重新挑战治疗中对不耐受的病人补充维生素D
Alison L P Compton,Marc J Pepin,Daniel R Katzenberger et al.
Alison L P Compton et al.